Non-Metastatic Castration Resistant Prostate Cancer (Nmcrpc) Treatment Market size is expected to reach USD 15 Billion by the end of 2035, growing at a CAGR of 5% during the forecast period, i.e., 2023-2035. In the year 2022, the market size of non-metastatic castration resistant prostate cancer (NMcrpc) was USD 7 Billion. The growth of the market can be attributed to the increasing geriatric population and the rising prevalence of non-metastatic castration-resistant prostate cancer amongst individuals on a global level. People above 50 have a higher chance to be diagnosed with nmCRPC, therefore, the surge in the geriatric population is anticipated to be one of the major growth factors of the market. According to the data collected by the National Cancer Institute of the U.S. Department of Health and Human Services, in 2020, the estimated new cases and the number of deaths from prostate cancer in the U.S. were 191,930 and 33,330, respectively.
In addition to these, global non-metastatic castration resistant prostate cancer (NMcrpc) market trends such as Extensive research associated with cancer treatment in western countries, along with the growing investment in the development of advanced therapies are expected to fuel the progress of the market during the forecast period. People nowadays are more aware of early diagnosis of cancer owing to the surge in awareness and launch of the various government program to promote the treatment of cancer. For instance, in India government programs such as Health Minister’s Cancer Patient Fund, National Health Protection Scheme, and others are observed to be quite beneficial to get cancer treatment. Hence, all these factors are anticipated to influence the market growth over the forecast period.
Growth Drivers
Growing Prevalence of Prostate Cancer – the main cause of prostate cancer is still not known, although aging can be a major factor in this disease. Additionally, ethnic group factor has also been noticed where black men were more likely to get prostate cancer than Asian men. For instance, it was estimated that around 100 new cases of prostate cancer are diagnosed every year per 100,000 men across the globe.
Rising Geriatric Population Across the Globe – growth in the geriatric population is expected to be one of the major factors to boost the market growth over the forecast period since it has been noticed by medical professionals that the chances of prostate cancer are much higher in men above 50. For instance, data represented by the World Bank, it was stated that in 2021, the global geriatric population reached 758,631,369 which was an increase from 737,138,709 in 2020.
Increasing Instances of Other Types of Cancer - non-metastatic castration-resistant prostate cancer (nmCRPC) treatment methods are also utilized to treat other types of cancers as well such as breast, lung, skin, and other cancer. Cancer has been considered to be the leading cause of death across the globe. The prevalence of cancer is presented by incidents and survival rate. For instance, in women, the prevalence of breast cancer was high in women reaching approximately 42% while in men, prostate cancer was observed to be most prevalent reaching approximately 43% in 2019.
Growth in the Investment and R&D Activities in the Oncology Segment – owing to the escalating prevalence of cancer around the world, a surge in R&D activities to find cures for cancer can be observed. As of 2021, global cancer research and development activities were estimated to grow by 50%.
Rising Development of New Drugs and Biomarkers – the utilization of biomarkers is noticed to be very high in clinical trials where approximately 50% of the clinical trials used biomarkers in 2018.
Challenges
The non-metastatic castration-resistant prostate cancer treatment is expected to be very expensive since depending on the type and its stage, healthcare providers give various types of therapy such as particle therapy, brachytherapy, chemotherapy, hormonal therapy, radiosurgery, and others.All of them require plenty of money and it also increases based on the duration of treatment. Hence, this factor is expected to limit the growth of the market over the forecast period.
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~5% |
|
Base Year Market Size (2022) |
~ USD 7 Billion |
|
Forecast Year Market Size (2035) |
~ USD 15 Billion |
|
Regional Scope |
|
Therapy Type (Chemotherapy, Immunotherapy, Radiotherapy, Hormonal Therapy)
The global non-metastatic castration resistant prostate cancer (nmCRPC) treatment market is segmented and analyzed for demand and supply by therapy type into chemotherapy, immunotherapy, radiotherapy, hormonal therapy, and others. Out of these types, the hormonal therapy segment is estimated to gain the largest market share in the year 2035. The growth of the segment can be attributed to the higher positive diagnosis rates and better efficiency of hormonal therapy than chemotherapy. Moreover, hormonal therapy is widely being used as an adjuvant treatment alongside radiation therapy and surgery, which is also projected to contribute to the growth of the segment during the forecast period. hormonal therapy has been observed to be the most effective method to stop or slow down the growth of cancer, especially, prostate and breast cancer since these types of cancers use hormones to grow. Hence, the higher prevalence of breast cancer is further expected to hike the segment growth over the forecast period. For instance, as of 2020, nearly 650,000 women lost their lives owing to breast cancer across the globe.
Application (General Medical & Surgical Hospitals, Specialty Hospitals, Clinics)
The global non-metastatic castration resistant prostate cancer (nmCRPC) treatment market is also segmented and analyzed for demand and supply by application into general medical & surgical hospitals, specialty hospitals, clinics, and others. The specialty hospitals segment is expected to lead the market over the forecast period. The growth of the segment can be attributed to the fact that nmCRPC is a relatively rare occurrence and as a result, a considerable portion of the population with this cancer on a global level tends to choose healthcare facilities specializing in its treatment. Since specialty is known to target one specific area of care and medicine and these hospitals are generally owned by physicians themselves. Specialty hospitals include cardiac facilities, orthopedic centers, and surgical centers. Hence, these are the hospital devoted to specialized care, enhanced and treatment of long-term illness, injury, cancer diagnostics, and infirmity. For instance, in the United States, the specialty hospital industry is anticipated to grow by approximately 2% in 2023 which sums up to around USD 60 billion. Hence, all these factors are projected to hike the market growth over the forecast period.
Our in-depth analysis of the global market includes the following segments:
|
By Therapy Type |
|
|
By Application |
|
North American Market Forecast
The North America non-metastatic castration resistant prostate cancer (nmCRPC) treatment market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The growth of the market can be attributed majorly to the increasing awareness about nmCRPC and the need to develop innovative cancer treatment solutions in the region. Furthermore, in 2021, the market in North America was expected to hold the largest share in terms of revenue, owing to the growing investment of governmental and non-governmental agencies in cancer screening & research, accompanied by the presence of leading healthcare service providers in the region. Along with this, North America also leads in terms of ongoing clinical trials, which is also expected to contribute to the market growth in the region. North America is known to be the most prevalent region of cancer. For instance, as of 2018, out of 1 million cancer cases, around 12% of them were projected to be prostate cancer in North America.
Europe Market Forecast
The European non-metastatic castration resistant prostate cancer (nmCRPC) treatment market, amongst the market in all the other regions, is projected to hold the second largest share during the forecast period. the market in Europe is also anticipated to occupy a significant share in the mnCRPC treatment market on account of its proven success in terms of drug development and the high incidence of prostate cancer in the region. As per the analysis of the European Commission, prostate cancer is ranked first among the most widely diagnosed cancer among men in the European Union. For instance, it was estimated that approximately 50,000 new prostate cancer are diagnosed in the United Kingdom every year which sums up to 135 cases every day. Apart from that, nearly 12,000 people died owing to prostate cancer in the region between 2017-2029. Hence, all these statistics about prostate cancer are estimated to expand the market size over the forecast period.
Astellas Pharma Inc. to conduct clinical trials to develop cell therapy. The development pipeline of the company includes high unmet medical needs such as autoimmune & cardiovascular diseases and cancer. The cell therapy research of the company is based on pluripotent stem cells (PSC)
Clovis Oncology, Inc. to present data from Phase 3 trial, “TRITON3: A Phase 3 Study of Rucaparib vs. Physician’s Choice of Therapy inmCRPC Associated with Homologous Recombination Deficiency (HRD)”. The trial is associated with men with metastatic castration-resistant prostate cancer.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?